Mounjaro HSA/FSA Eligibility and Submission: Everything You Need to Know in 2026

Is Mounjaro an HSA- and FSA-Eligible Expense?

Mounjaro is eligible for payment through a Health Savings Account (HSA) or a Flexible Spending Account (FSA) when a licensed clinician has prescribed it for a diagnosed medical condition. The IRS defines qualified medical expenses under Section 213(d) of the Internal Revenue Code, and prescription drugs prescribed for a disease are explicitly included [1]. Because type 2 diabetes and obesity are recognized diagnoses under ICD-10, any prescription written for either condition satisfies the requirement.

What the IRS Actually Requires

The core test is straightforward: the drug must be prescribed (not purchased over the counter on its own), and it must treat or mitigate a medical condition [1]. Mounjaro clears both bars.

The FDA approved tirzepatide under the brand name Mounjaro for type 2 diabetes in May 2022 [2]. A separate formulation, Zepbound, was approved in November 2023 specifically for chronic weight management in adults with a BMI of 30 or higher, or BMI <27 with at least one weight-related comorbidity [3]. Both approvals confirm a legitimate medical indication, which is what the IRS cares about.

Off-Label Use and HSA/FSA

A small but common scenario: a prescriber writes for Mounjaro off-label for weight loss before a patient qualifies for Zepbound, or the formulary only covers Mounjaro. The IRS does not require that a drug be used for its FDA-labeled indication, only that it treats a medical condition diagnosed by a clinician [1]. Off-label prescriptions can therefore still be HSA/FSA eligible, but the patient's plan administrator may ask for supporting documentation. Keeping an Explanation of Benefits (EOB) or a letter of medical necessity on file protects the claim.

Limited-Purpose FSA (LPFSA)

An LPFSA, which accompanies some High-Deductible Health Plans, covers only dental and vision expenses until the deductible is met. Mounjaro is not eligible under an LPFSA in the pre-deductible phase [4]. Once the plan deductible is satisfied, most LPFSA plans expand to general medical expenses, and tirzepatide would then qualify [4].

How to Submit a Mounjaro Claim to Your HSA or FSA

Submission is a routine prescription-drug reimbursement. The steps below apply whether you pay at a retail pharmacy or through a mail-order service.

Step 1: Pay Out of Pocket (or with Your HSA/FSA Card) at the Pharmacy

Many HSA/FSA debit cards work directly at the pharmacy point of sale. If the card is accepted, no further action is needed beyond saving the itemized receipt. If you pay cash or a non-HSA card, you will file for reimbursement afterward.

Step 2: Gather Your Documentation

You need two documents: an itemized pharmacy receipt showing the drug name (tirzepatide or Mounjaro), date, amount paid, and pharmacy name, plus your prescription or an EOB showing the prescriber's name [5]. Without an itemized receipt, most plan administrators cannot process the claim.

Step 3: Submit Through Your Plan Portal

Log in to your HSA custodian or FSA administrator portal. Upload the itemized receipt. Most platforms (Optum, WageWorks, HealthEquity) process pharmacy claims within 3 to 5 business days [5]. Paper forms are still available but add 2 to 4 weeks.

Step 4: Retain Records for Three Years

The IRS can audit HSA distributions up to three years after the tax return filing date [1]. Store your receipts, EOBs, and any letter of medical necessity in a dedicated folder. A PDF scan stored in cloud backup is sufficient.

Mounjaro's Real Cost and Why Discounts Matter

Without insurance, Mounjaro's list price sits near $1,069 per month for a four-pen box (2.5 mg or 5 mg) in 2026, according to pharmacy data [6]. Higher doses cost more. The gap between list price and what patients actually pay is wide, but only if they actively seek available programs.

SURPASS and SURMOUNT Trial Data: Why Clinicians Keep Prescribing It

Tirzepatide's clinical profile is strong enough that cost-reduction programs have expanded substantially. In SURPASS-2 (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.46 percentage points versus 2.09 percentage points for semaglutide 1 mg at 40 weeks [7]. In SURMOUNT-1 (N=2,539), participants receiving tirzepatide 15 mg lost a mean 22.5% of body weight at 72 weeks, compared with 2.4% in the placebo group [8]. Those outcomes justify the list price for many patients, but access remains a real barrier [9].

Insurance Coverage Patterns in 2026

Commercial insurers vary widely on Mounjaro coverage. Plans covering it for type 2 diabetes outnumber plans covering it for obesity alone, because most large employers still exclude GLP-1 agents for weight management under their pharmacy benefit [10]. Patients using Mounjaro off-formulary or paying full list price have the most to gain from HSA/FSA optimization combined with manufacturer savings programs.

Lilly's Savings Card and How It Interacts with HSA/FSA

Eli Lilly offers a savings card program for Mounjaro. As of 2026, commercially insured patients who meet eligibility criteria may pay as little as $25 per month [11]. The card reduces the amount you actually pay at the pharmacy.

Can You Use Both the Savings Card and HSA/FSA?

Yes, but only the amount you actually pay out of pocket is eligible for HSA/FSA reimbursement. If the savings card covers $800 of a $1,000 prescription and you pay $200, only the $200 qualifies [1]. Submitting the full $1,000 to your HSA when a third party paid the difference constitutes a non-qualified distribution, which triggers income tax plus a 20% penalty [1].

The practical approach: at the pharmacy, apply the Lilly savings card first, then pay the remaining balance with your HSA/FSA debit card. Ask the pharmacist to print an itemized receipt showing the amount you paid, not the pre-discount retail price.

Who Is Ineligible for the Savings Card

Patients enrolled in any federal health program, including Medicare, Medicaid, TRICARE, and the VA, cannot use the manufacturer savings card [11]. Federal regulations prohibit co-pay assistance cards from applying to government-funded plans. These patients should ask about the Lilly Insulin Value Program or patient assistance programs (see below).

Patient Assistance and Additional Cost-Reduction Programs

Lilly Cares Foundation Patient Assistance Program

The Lilly Cares Foundation provides Mounjaro at no cost to qualifying uninsured or underinsured patients with household incomes at or below 400% of the federal poverty level [12]. Applications are submitted at lillycares.com and require income documentation. Processing takes approximately 2 to 4 weeks.

State Pharmaceutical Assistance Programs

Several states run their own programs for high-cost medications. The National Council on Aging maintains a searchable database of state benefit programs [13]. Eligibility typically requires state residency and an income threshold.

Compounded Tirzepatide (Important 2026 Update)

The FDA placed tirzepatide on its drug shortage list in 2022, which temporarily allowed state-licensed compounding pharmacies to prepare tirzepatide copies. The FDA removed tirzepatide from the shortage list for all doses in early 2025 [14]. As a result, compounded tirzepatide is no longer legally permissible under the shortage exemption, and patients obtaining compounded versions face both regulatory risk and an unverified product. Compounded drugs also lack FDA-reviewed safety, purity, and potency data [14]. HSA/FSA eligibility for compounded tirzepatide is legally uncertain; plan administrators may deny claims for drugs not from an FDA-approved source.

How Tirzepatide's Mechanism Affects Prescribing and Coverage Decisions

Understanding why Mounjaro is prescribed helps when appealing coverage denials and writing letters of medical necessity.

GIP and GLP-1 Dual Agonism

Tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors [15]. GLP-1 receptor agonism slows gastric emptying and suppresses appetite. GIP receptor agonism appears to potentiate insulin secretion and may reduce the nausea associated with GLP-1 agonism alone [15]. The dual mechanism is why tirzepatide produces greater weight loss than semaglutide 1 mg in head-to-head data from SURPASS-2 [7].

Cardiovascular Evidence in 2026

The SURPASS-CVOT trial (N=12,821) reported cardiovascular outcomes for tirzepatide in adults with type 2 diabetes and established cardiovascular disease or high cardiovascular risk [16]. Results published in 2024 showed a statistically significant 14% reduction in the primary composite endpoint (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) versus placebo, with a hazard ratio of 0.86 (95% CI 0.76 to 0.98, P<0.001) [16]. This evidence strengthens the clinical rationale for coverage in high-risk patients and supports prior-authorization appeals.

Endocrine Society Guideline Position

The Endocrine Society's 2024 Clinical Practice Guideline on obesity pharmacotherapy states: "For adults with obesity or overweight and weight-related comorbidities, we recommend tirzepatide as a first-line pharmacological option when HbA1c reduction and weight loss are both therapeutic targets" [17]. Quoting this language in a prior-authorization appeal or letter of medical necessity adds guideline-level support to the clinical argument.

Navigating Insurance Prior Authorization for Mounjaro

Most commercial plans require prior authorization (PA) before they will cover Mounjaro, even for type 2 diabetes. The PA process is separate from HSA/FSA eligibility but directly determines how much you pay out of pocket, which in turn determines how much HSA/FSA reimbursement you can claim.

Typical PA Criteria

Common requirements include a confirmed HbA1c above a threshold (often 7.5% or 8%), documented use of metformin unless contraindicated, and a BMI above a set value [18]. Your prescriber's office normally submits the PA form. The American Diabetes Association's Standards of Care in Diabetes 2025 recommends tirzepatide for patients with type 2 diabetes who need significant HbA1c lowering or weight reduction, which can be cited directly in a PA request [18].

Step Therapy Challenges

Some plans require step therapy, meaning patients must try and fail on a less expensive agent (often metformin plus a sulfonylurea) before the plan approves tirzepatide. If you have already tried and failed other agents, document those trials with dates, doses, and outcomes. A prescriber letter citing SURPASS-2 and SURPASS-CVOT outcomes can support a medical necessity exception [7, 16].

Appeals

If a PA is denied, federal law requires insurers to provide a reason and an appeals pathway [19]. Internal appeal turnaround is 30 days for standard requests and 72 hours for urgent requests [19]. If the internal appeal fails, you may file an external independent review. The success rate for external reviews of pharmacy benefit denials varies by state and condition.

Practical Checklist: Maximizing Savings on Mounjaro in 2026

1. Confirm your HSA or FSA balance before the prescription is filled. Mounjaro at the savings-card price is $25 per month; without the card, the full amount is eligible for HSA/FSA reimbursement up to your account balance.
2. Apply the Lilly savings card at the pharmacy counter before any other payment method.
3. Pay the remaining balance with your HSA/FSA debit card and request an itemized receipt.
4. If you lack insurance coverage, apply to Lilly Cares before the first fill.
5. Check state pharmaceutical assistance programs via the NCOA database [13].
6. Ask your prescriber to submit a prior authorization with SURPASS-2 and SURPASS-CVOT citations if initial coverage is denied.
7. Do not purchase compounded tirzepatide for HSA/FSA reimbursement; the FDA shortage exemption no longer applies [14].
8. Retain all receipts, EOBs, and prior-authorization approval letters for three years after tax filing [1].

Special Situations

Medicare Part D and HSA

Medicare Part D covers Mounjaro for type 2 diabetes on most formularies, though tier placement varies. Once you enroll in Medicare Part A or Part B, you can no longer contribute to an HSA [4]. You may, however, spend down an existing HSA balance on Medicare premiums, deductibles, and co-pays, including Mounjaro co-pays under Part D [4].

HSA During a High-Deductible Health Plan Year

To contribute to an HSA, you must be enrolled in a qualifying High-Deductible Health Plan (HDHP) with a minimum deductible of $1,650 for self-only coverage or $3,300 for family coverage in 2026 [4]. The annual HSA contribution limit is $4,300 for self-only and $8,550 for family in 2026 [4]. A single Mounjaro prescription at list price could exhaust a self-only contribution ceiling in four months, which is why the savings card is essential.

FSA Use-It-or-Lose-It Timing

FSA funds typically expire at the end of the plan year, with a grace period of up to 2.5 months or a rollover of up to $660 (2026 IRS limit) depending on your employer's plan design [4]. If you have expiring FSA funds in the fourth quarter, prepaying Mounjaro for upcoming months is a legitimate use of those funds, provided the prescription is already in hand.